PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
16.61%
Some net income increase while AVXL is negative at -31.68%. John Neff would see a short-term edge over the struggling competitor.
4.17%
D&A growth of 4.17% while AVXL is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
-100.00%
Negative yoy deferred tax while AVXL stands at 0.00%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
-2.08%
Negative yoy SBC while AVXL is 42.19%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-115.45%
Both reduce yoy usage, with AVXL at -0.58%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-138.13%
Negative yoy AP while AVXL is 2475.07%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
-68.80%
Both reduce yoy usage, with AVXL at -23.41%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
119.47%
Lower 'other non-cash' growth vs. AVXL's 2475.07%, indicating steadier reported figures. David Dodd would confirm no missed necessary write-downs or gains.
9.84%
Some CFO growth while AVXL is negative at -25.85%. John Neff would note a short-term liquidity lead over the competitor.
98.37%
CapEx growth of 98.37% while AVXL is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
98.37%
We expand invests by 98.37% while AVXL is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
64.41%
Debt repayment growth of 64.41% while AVXL is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
-34.38%
Negative yoy issuance while AVXL is 217.57%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.